ESMO 2017: Immunotherapy with durvalumab improves progression-free survival in patients with stage III NSCLC

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Durvalumab, a new immunotherapy agent, improves progression-free survival in patients with locally advanced, unresectable stage III non-small-cell lung cancer according to the PACIFIC phase 3 trial.
  • Durvalumab, an inhibitor of programmed death-ligand 1, could be considered now as ...